Oslo Cancer Cluster is hosting a Super Session at the Nordic Life Science Days in Stockholm. International thought leaders will discuss current game changing innovations and their impact on the industry in the years ahead.
Oncology is at the forefront of realizing the promises of precision medicine. Huge and complex datasets are exploited for novel drug development as well as for informed and real-time care decisions. Emerging Cancer immunotherapies represent a paradigm shift for cancer treatment triggering a global R&D race and novel partnerships. Furthermore, the convergence of the genetics and digital revolution creates novel types of products, companies and growth opportunities transforming the sector.
Moderator: Mr. Richard Godfrey, CEO, BergenBio, Norway
|5||Introduction by moderator||· Dr. Richard Godfrey, CEO BerGenBio
|10||Topic 1 –global company – perspectives from industry leader – Precision Medicine||· Dr. Vaios Karanikas, Senior Biomarker and Experimental Medicine Leader, Tumor Immunology, Roche Pharmaceutical Research and Early Development, Innovation Center Zurich|
|10||Topic 2 – Digital Health company – Big Data / artificial intelligence -> impact on cancer R&D and care||· Dr. Anthony Bak, Principal Data Scientist, Ayasdi|
|10||Topic 3 – global company – perspectives from industry leader – Immuno-Oncology||· Dr. Tim Fisher, Global Lead, Immuno-Oncology / Oncology, Search & Evaluation, Bristol-Myers Squibb|
|25||Panel Discussion||· All speakers, joined by Dr. Erik Lund, Director, Worldwide Licensing at MSD (Merck & Co., Inc.)|
Target Audience: Start-ups, Biotechs, Pharma, investors, academic innovators, TTOs